Report preliminary efficacy and safety results for riliprubart, a novel complement C1s-inhibitor, in people with CIDP.
No takes yet. Share an insight, caveat, or question.
Querol et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: